Sarpogrelate Hydrochloride, a Selective 5-HT_2A Receptor Antagonist, Improves Skin Perfusion Pressure of the Lower Extremities in Hemodialysis Patients with Peripheral Arterial Disease

REFERENCES

• Okamoto K, Oka M, Maesato K, . Peripheral arterial occlusive disease is more prevalent in patients with hemodialysis: comparison with the findings of multidetector-row computed tomography. Am J Kidney Dis. 2006;48:269–276.
   PubMed Web of Science ®Google Scholar
• O’Hare AM, Bertenthal D, Shlipak MG, Sen S, Chren MM. Impact of renal insufficiency on mortality in advanced lower extremity peripheral arterial disease. J Am Soc Nephrol. 2005;16:514–519.
   PubMed Web of Science ®Google Scholar
• Combe C, Albert JM, Bragg-Gresham JL, . The burden of amputation among hemodialysis patients in the dialysis outcomes and practice patterns study. Am J Kidney Dis. 2009;54:680–692.
   PubMed Web of Science ®Google Scholar
• Leskinen Y, Salenius JP, Lehtimaeki T, Huhtala H, Saha H. The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: requirements for diagnostics. Am J Kidney Dis. 2002;40:472–479.
   PubMed Web of Science ®Google Scholar
• Ohtake T, Oka M, Ikee R, . Impact of lower limbs’ arterial calcification on the prevalence and severity of PAD in patients on hemodialysis. J Vasc Surg. 2011;53:676–683.
   PubMedGoogle Scholar
• Castronuovo JJ, Adera HM, Smiell JM, Price RM. Skin perfusion pressure measurement is valuable in the diagnosis of critical limb ischemia. J Vasc Surg. 1997;24:629–637.
   Google Scholar
• Norgren L, Hiatt WR, Dormandy JA, . Inter-society consensus for the management of peripheral arterial disease. Int Angiol. 2007;26:81–157.
   PubMed Web of Science ®Google Scholar
• Hara H, Osakabe M, Kitajima A, Tamao Y, Kikumoto R. MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist. J Thromb Hemost. 1991;65:415–420.
   PubMed Web of Science ®Google Scholar
• Norgren L, Jawien A, Matyas L, Riegerd H, Arita K. Sarpogrelate, a 5-hT2A receptor antagonist in intermittent claudication. A phase II European study. Vasc Med. 2006;11:75–83.
   PubMed Web of Science ®Google Scholar
• Matsuo H, Shigematsu H. Effects of the 5-HT2A antagonist sarpogrelate on walking ability in patients with intermittent claudication as measured using the walking impairment questionnaire. Ann Vasc Dis. 2008;1:102–110.
   PubMedGoogle Scholar
• Rajagopalan S, Dellegrottaglie S, Furnisss AL, . Peripheral arterial disease in patients with end-stage renal disease: observations from the dialysis outcomes and practice patterns study (DOPPS). Circulation. 2006;114:1914–1922.
   PubMed Web of Science ®Google Scholar
• Kondo Y, Muto A, Dardik A, Nishibe M, Nishibe T. Laser Doppler skin perfusion pressure in the diagnosis of limb ischemia in patients with diabetes mellitus and/or hemodialysis. Int Angiol. 2007;26:258–261.
   PubMed Web of Science ®Google Scholar
• Carter SA. Clinical measurement of systolic pressures in limbs with arterial occlusive disease. J Am Med Assoc. 1969;207: 1869–1874.
   PubMed Web of Science ®Google Scholar
• Nishihira K, Yamashita A, Tanaka N, . Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery. J Thromb Hemost. 2006;4:247–255.
   Web of Science ®Google Scholar
• Barradas MA, Gill DS, Fonseca VA, Mikhailidis DP, Dandona P. Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest. 1988;4:399–404.
   Google Scholar
• Cheng CH, Cheng FC, Shu KH, Wu MJ. Abnormal serotonin metabolism in long-term hemodialysis and CAPD patients. Am J Nephrol. 1997;17:541–542.
   PubMed Web of Science ®Google Scholar
• Hoyer D, Clarke DE, Fozard JR, . International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev. 1994;46:157–203.
   PubMed Web of Science ®Google Scholar
• Nagatomo T, Rashid M, Abul Muntasir H, Komiyama T. Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. Pharmacol Ther. 2004;104:59–81.
   PubMed Web of Science ®Google Scholar
• Makita Z, Bucala R, Rayfield EJ, . Reactive glycosylation endproducts in diabetic uremia and treatment of renal failure. Lancet. 1994;343:1519–1522.
   PubMed Web of Science ®Google Scholar
• Taki K, Takayama F, Tsuruta Y, Niwa T. Oxidative stress, advanced glycation end product, and coronary artery calcification in hemodialysis patients. Kidney Int. 2006;70:218–224.
   PubMed Web of Science ®Google Scholar
• Shigematsu S, Takahashi N, Hara M, Yoshimatsu H, Saikawa T. Increased incidence of coronary in-stent restenosis in type 2 diabetic patients is related to elevated serum malondialdehyde-modified low-density lipoprotein. Circ J. 2007;71:1697–1702.
   PubMed Web of Science ®Google Scholar
• Mikawa K, Akamatsu H, Nishina K, et al. The effects of sarpogrelate on superoxide production by human neutrophils. Reg Anesth Pain Med. 2000;25:181–186.
   PubMed Web of Science ®Google Scholar
• Sun YM, Su Y, Jin HB, . Sarpogrelate protects against high glucose-induced endothelial dysfunction and oxidative stress. Int J Cardiol. 2011;147:383–387.
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Higashi Y, Goto C, . Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease. J Cardiovasc Pharmacol. 2007;49:221–227.
   PubMed Web of Science ®Google Scholar
• Iseki K, Nakai S, Yamagata K, . Tachycardia as a predictor of poor survival in chronic hemodialysis patients. Neprol Dial Transplant. 2011;26:963–969.
   PubMed Web of Science ®Google Scholar